JP2024503699A5 - - Google Patents
Info
- Publication number
- JP2024503699A5 JP2024503699A5 JP2023543035A JP2023543035A JP2024503699A5 JP 2024503699 A5 JP2024503699 A5 JP 2024503699A5 JP 2023543035 A JP2023543035 A JP 2023543035A JP 2023543035 A JP2023543035 A JP 2023543035A JP 2024503699 A5 JP2024503699 A5 JP 2024503699A5
- Authority
- JP
- Japan
- Prior art keywords
- protein
- cov
- sars
- reading frame
- open reading
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (19)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163138228P | 2021-01-15 | 2021-01-15 | |
| US63/138,228 | 2021-01-15 | ||
| US202163140920P | 2021-01-24 | 2021-01-24 | |
| US63/140,920 | 2021-01-24 | ||
| US202163161433P | 2021-03-15 | 2021-03-15 | |
| US63/161,433 | 2021-03-15 | ||
| US202163173979P | 2021-04-12 | 2021-04-12 | |
| US63/173,979 | 2021-04-12 | ||
| US202163193547P | 2021-05-26 | 2021-05-26 | |
| US63/193,547 | 2021-05-26 | ||
| US202163222925P | 2021-07-16 | 2021-07-16 | |
| US63/222,925 | 2021-07-16 | ||
| US202163241963P | 2021-09-08 | 2021-09-08 | |
| US63/241,963 | 2021-09-08 | ||
| US202163283905P | 2021-11-29 | 2021-11-29 | |
| US63/283,905 | 2021-11-29 | ||
| US202163284570P | 2021-11-30 | 2021-11-30 | |
| US63/284,570 | 2021-11-30 | ||
| PCT/US2022/012614 WO2022155530A1 (en) | 2021-01-15 | 2022-01-14 | Variant strain-based coronavirus vaccines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024503699A JP2024503699A (ja) | 2024-01-26 |
| JP2024503699A5 true JP2024503699A5 (https=) | 2025-04-14 |
Family
ID=80168090
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023543035A Pending JP2024503699A (ja) | 2021-01-15 | 2022-01-14 | バリアント株ベースのコロナウイルスワクチン |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20240139309A1 (https=) |
| EP (1) | EP4277653A1 (https=) |
| JP (1) | JP2024503699A (https=) |
| AU (1) | AU2022207495A1 (https=) |
| CA (1) | CA3208303A1 (https=) |
| WO (1) | WO2022155530A1 (https=) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PL4023249T3 (pl) | 2014-04-23 | 2025-03-10 | Modernatx, Inc. | Szczepionki z kwasem nukleinowym |
| MA42543A (fr) | 2015-07-30 | 2018-06-06 | Modernatx Inc | Arn épitope peptidiques concatémériques |
| US11564893B2 (en) | 2015-08-17 | 2023-01-31 | Modernatx, Inc. | Methods for preparing particles and related compositions |
| AU2016341309A1 (en) | 2015-10-22 | 2018-06-07 | Modernatx, Inc. | Cancer vaccines |
| EP4011451A1 (en) | 2015-10-22 | 2022-06-15 | ModernaTX, Inc. | Metapneumovirus mrna vaccines |
| WO2017201342A1 (en) | 2016-05-18 | 2017-11-23 | Modernatx, Inc. | Polynucleotides encoding jagged1 for the treatment of alagille syndrome |
| CA3036831A1 (en) | 2016-09-14 | 2018-03-22 | Modernatx, Inc. | High purity rna compositions and methods for preparation thereof |
| MA46766A (fr) | 2016-11-11 | 2019-09-18 | Modernatx Inc | Vaccin antigrippal |
| WO2018170245A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Broad spectrum influenza virus vaccine |
| WO2018170256A1 (en) | 2017-03-15 | 2018-09-20 | Modernatx, Inc. | Herpes simplex virus vaccine |
| US11905525B2 (en) | 2017-04-05 | 2024-02-20 | Modernatx, Inc. | Reduction of elimination of immune responses to non-intravenous, e.g., subcutaneously administered therapeutic proteins |
| MA49421A (fr) | 2017-06-15 | 2020-04-22 | Modernatx Inc | Formulations d'arn |
| MA49914A (fr) | 2017-08-18 | 2021-04-21 | Modernatx Inc | Procédés analytiques par hplc |
| WO2019036682A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | RNA VARIANTS POLYMERASE |
| EP3675817A1 (en) | 2017-08-31 | 2020-07-08 | Modernatx, Inc. | Methods of making lipid nanoparticles |
| EP3746090A4 (en) | 2018-01-29 | 2021-11-17 | ModernaTX, Inc. | RSV RNA Vaccines |
| CA3113025A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | Peg lipids and uses thereof |
| WO2020061295A1 (en) | 2018-09-19 | 2020-03-26 | Modernatx, Inc. | High-purity peg lipids and uses thereof |
| WO2020061457A1 (en) | 2018-09-20 | 2020-03-26 | Modernatx, Inc. | Preparation of lipid nanoparticles and methods of administration thereof |
| AU2020224103A1 (en) | 2019-02-20 | 2021-09-16 | Modernatx, Inc. | Rna polymerase variants for co-transcriptional capping |
| CN113874502A (zh) | 2019-03-11 | 2021-12-31 | 摩登纳特斯有限公司 | 补料分批体外转录方法 |
| US12070495B2 (en) | 2019-03-15 | 2024-08-27 | Modernatx, Inc. | HIV RNA vaccines |
| US12194089B2 (en) | 2020-02-04 | 2025-01-14 | CureVac SE | Coronavirus vaccine |
| US11918643B2 (en) | 2020-12-22 | 2024-03-05 | CureVac SE | RNA vaccine against SARS-CoV-2 variants |
| EP4274607A1 (en) | 2021-01-11 | 2023-11-15 | ModernaTX, Inc. | Seasonal rna influenza virus vaccines |
| US20220363937A1 (en) | 2021-05-14 | 2022-11-17 | Armstrong World Industries, Inc. | Stabilization of antimicrobial coatings |
| TWI844087B (zh) * | 2021-09-02 | 2024-06-01 | 高端疫苗生物製劑股份有限公司 | 抗新型冠狀病毒(SARS-CoV-2)變異株之免疫組合物及方法 |
| US12397051B2 (en) * | 2021-09-14 | 2025-08-26 | Globe Biotech Limited | Vaccine for use against coronavirus and variants thereof |
| WO2023092069A1 (en) * | 2021-11-18 | 2023-05-25 | Modernatx, Inc. | Sars-cov-2 mrna domain vaccines and methods of use |
| US12186387B2 (en) | 2021-11-29 | 2025-01-07 | BioNTech SE | Coronavirus vaccine |
| US12529047B1 (en) | 2021-12-21 | 2026-01-20 | Modernatx, Inc. | mRNA quantification methods |
| WO2024002985A1 (en) | 2022-06-26 | 2024-01-04 | BioNTech SE | Coronavirus vaccine |
| JP2025529906A (ja) * | 2022-08-22 | 2025-09-09 | ザ ヘンリー エム ジャクソン ファンデイション フォー ザ アドヴァンスメント オブ ミリタリー メディシン インコーポレイテッド | コロナウイルスに対するワクチン |
| WO2024050483A1 (en) * | 2022-08-31 | 2024-03-07 | Modernatx, Inc. | Variant strain-based coronavirus vaccines and uses thereof |
| WO2024083178A1 (en) * | 2022-10-19 | 2024-04-25 | Immorna (hangzhou) Biotechnology Co., Ltd. | Gene of interest rna formulations |
| EP4608442A1 (en) | 2022-10-28 | 2025-09-03 | GlaxoSmithKline Biologicals S.A. | Nucleic acid based vaccine |
| CN117567571A (zh) * | 2023-09-28 | 2024-02-20 | 上海蓝鹊生物医药有限公司 | 一种抗新冠病毒的蛋白或mRNA疫苗及其制备方法和应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2340499T3 (es) | 2001-06-05 | 2010-06-04 | Curevac Gmbh | Arnm de antigeno tumoral estabilizado con un contenido de g/c aumentado. |
| US9012219B2 (en) | 2005-08-23 | 2015-04-21 | The Trustees Of The University Of Pennsylvania | RNA preparations comprising purified modified RNA for reprogramming cells |
| DE102005046490A1 (de) | 2005-09-28 | 2007-03-29 | Johannes-Gutenberg-Universität Mainz | Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen |
| JP2010531640A (ja) | 2007-06-29 | 2010-09-30 | コモンウェルス サイエンティフィック アンド インダストリアル リサーチ オーガニゼイション | 毒性化合物の分解方法 |
| CA2715078C (en) | 2007-09-26 | 2019-07-23 | Intrexon Corporation | Synthetic 5'utrs, expression vectors, and methods for increasing transgene expression |
| SG10201408162PA (en) | 2007-12-11 | 2015-01-29 | Scripps Research Inst | Compositions and methods related to mrna translational enhancer elements |
| RU2013154295A (ru) | 2011-06-08 | 2015-07-20 | Шир Хьюман Дженетик Терапис, Инк. | КОМПОЗИЦИИ ЛИПИДНЫХ НАНОЧАСТИЦ И СПОСОБЫ ДЛЯ ДОСТАВКИ мРНК |
| EP2858679B2 (en) | 2012-06-08 | 2024-06-05 | Translate Bio, Inc. | Pulmonary delivery of mrna to non-lung target cells |
| EP3388834B1 (en) | 2013-03-15 | 2020-04-15 | Translate Bio, Inc. | Synergistic enhancement of the delivery of nucleic acids via blended formulations |
| WO2014152027A1 (en) | 2013-03-15 | 2014-09-25 | Moderna Therapeutics, Inc. | Manufacturing methods for production of rna transcripts |
| KR102354389B1 (ko) | 2013-08-21 | 2022-01-20 | 큐어백 아게 | Rna―암호화된 단백질의 발현을 증가시키는 방법 |
| WO2015062738A1 (en) | 2013-11-01 | 2015-05-07 | Curevac Gmbh | Modified rna with decreased immunostimulatory properties |
| CN111304231A (zh) | 2013-12-30 | 2020-06-19 | 库瑞瓦格股份公司 | 人工核酸分子 |
| CA2927254C (en) | 2013-12-30 | 2023-10-24 | Curevac Ag | Artificial nucleic acid molecules |
| US9259829B1 (en) | 2014-08-25 | 2016-02-16 | Cougar Holdings, Llc | Roofing and nail removal hammer |
| EP3405579A1 (en) | 2016-01-22 | 2018-11-28 | Modernatx, Inc. | Messenger ribonucleic acids for the production of intracellular binding polypeptides and methods of use thereof |
| CA3036831A1 (en) | 2016-09-14 | 2018-03-22 | Modernatx, Inc. | High purity rna compositions and methods for preparation thereof |
| WO2019036682A1 (en) | 2017-08-18 | 2019-02-21 | Modernatx, Inc. | RNA VARIANTS POLYMERASE |
| JP2023511633A (ja) * | 2020-01-28 | 2023-03-20 | モデルナティエックス インコーポレイテッド | コロナウイルスｒｎａワクチン |
| KR20220144416A (ko) * | 2020-02-04 | 2022-10-26 | 큐어백 아게 | 코로나바이러스 백신 |
| CA3176481A1 (en) * | 2020-04-22 | 2021-10-28 | Marjoh NAUTA | Coronavirus vaccine |
| EP4146265A1 (en) * | 2020-05-07 | 2023-03-15 | Translate Bio, Inc. | Optimized nucleotide sequences encoding sars-cov-2 antigens |
-
2022
- 2022-01-14 JP JP2023543035A patent/JP2024503699A/ja active Pending
- 2022-01-14 AU AU2022207495A patent/AU2022207495A1/en not_active Abandoned
- 2022-01-14 CA CA3208303A patent/CA3208303A1/en active Pending
- 2022-01-14 EP EP22702382.7A patent/EP4277653A1/en active Pending
- 2022-01-14 US US18/272,496 patent/US20240139309A1/en active Pending
- 2022-01-14 WO PCT/US2022/012614 patent/WO2022155530A1/en not_active Ceased
-
2025
- 2025-08-08 US US19/294,594 patent/US20250367278A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2024503699A5 (https=) | ||
| JP2023513073A5 (https=) | ||
| JP2024503698A5 (https=) | ||
| JP7789819B2 (ja) | 核酸のデリバリーのための新規脂質および脂質ナノ粒子製剤 | |
| US20220347307A1 (en) | Messenger rna vaccines and uses thereof | |
| JP7150608B6 (ja) | 多量体コード核酸及びその使用 | |
| JP2024099679A (ja) | 層間エステル、チオエステル、ジスルフィドおよび無水部分を含む２，５－ジオキソピペラジン脂質 | |
| JP2024099745A5 (https=) | ||
| US12350383B2 (en) | Cationic lipids containing silicon | |
| KR102387898B1 (ko) | 핵산의 전달용 입체화학적으로 풍부한 조성물 | |
| JP2024059869A (ja) | メッセンジャーｒｎａの皮下送達 | |
| BR112019025224A2 (pt) | Terapêutica para doença de armazenamento de glicogênio tipo iii | |
| JP2012506254A5 (https=) | ||
| CA3044134A1 (en) | Improved compositions and methods for the delivery of nucleic acids | |
| JP7789103B2 (ja) | 原発性線毛機能不全症の治療のための組成物および方法 | |
| AU2010208035A1 (en) | Improved lipid formulation for the delivery of nucleic acids | |
| JP2018536689A5 (https=) | ||
| CA3151387A1 (en) | Lipid compositions for the delivery of therapeutic agents | |
| JP2022548399A5 (https=) | ||
| JP2021522804A5 (https=) | ||
| KR20220154740A (ko) | 간 성상 세포로 치료제의 지질 나노입자 전달을 위한 양이온성 지질 | |
| JP2024538859A5 (https=) | ||
| Payette et al. | Immune-mediated destruction of transfected myocytes following DNA vaccination occurs via multiple mechanisms | |
| CN121586722A (zh) | 产生对细菌感染的免疫力的组合物和方法 | |
| WO2025231114A1 (en) | Method of using lipid nanoparticles for intramuscular delivery |